 Mallinckrodt plc NYSE: MNK, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration FDA has accepted for review the Stratatech Biologics License Application BLA for StrataGraft, an investigational regenerative skin tissue therapy in development for the treatment of adult patients with deep partial-thickness thermal burns. The FDA granted the application priority review and assigned a Prescription Drug User Fee Act PDUFA target date of February 2, 2021. 